Return to homepagePandemic Pact

Pyridostigmine as immunomodulatory management in hospitalized patients with SARS-CoV-2 infection with severity criteria.

  • Funded by Consejo Nacional de Ciencia y Tecnología (CONACYT)
  • Total publications:4 publications

Grant number: 311790

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Consejo Nacional de Ciencia y Tecnología (CONACYT)

  • Principal Investigator

    N/A

  • Research Location

    Mexico

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Clinical Trials (Research Protocols In Human Beings) To Determine The Safety And Effectiveness Of Treatments (Of Recent Or Redirected Development1) For Covid-19.

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial.

Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.

Posterior reversible encephalopathy syndrome during convalescence from COVID-19.

Impacts of nitrogen deposition on herbaceous ground flora and epiphytic foliose lichen species in southern Ontario hardwood forests.